Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibo...
August 26 2020 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a
dedicated biologics contract development and manufacturing
organization (CDMO) working to improve patient lives by providing
high quality development and manufacturing services to
biotechnology and pharmaceutical companies, today announced that
Mapp Biopharmaceutical, Inc., has contracted Avid to provide
process transfer, scale-up and clinical manufacturing services to
support one of its development programs for a novel antiviral drug
candidate. Avid and Mapp will immediately commence the initial
phase of the project.
“We are extremely delighted and honored that
Mapp Biopharmaceutical, Inc. contracted Avid Bioservices as their
CDMO to support the company’s antiviral program. Today, we are all
too familiar with viral outbreaks and, as part of the scientific
community, we are proud to leverage our expertise to support the
prevention and treatment of challenging viruses,” said Timothy
Compton, chief commercial officer of Avid. “This agreement with
Mapp Biopharmaceutical provides further evidence of the significant
momentum that Avid’s business development team continues to
generate toward our dual goals of revenue growth and customer base
diversification. We are pleased to add Mapp to our growing list of
customers. We are eager to get to work so that we can efficiently
move toward CGMP manufacturing runs that will support Mapp’s
advancement of their product into clinical studies.”
Dr. Ron Aimes, Vice President of
Preclinical/Nonclinical Development and the program Principal
Investigator, commented, “Mapp is happy to partner with Avid
Bioservices to advance the development of our antiviral program
towards IND and first in human evaluation. Avid’s more than 20
years of experience in biologics manufacturing, positive track
record with regulatory agencies, extensive capabilities, and
manufacturing capacity will help us make this medical
countermeasure available for the United States as well as patients
around the globe quickly, safely, and efficiently.”
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical drug
substances derived from mammalian cell culture. The company
provides a comprehensive range of process development, CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 27 years of
experience producing monoclonal antibodies and recombinant
proteins, Avid's services include CGMP clinical and commercial drug
substance manufacturing, bulk packaging, release and stability
testing and regulatory submissions support. For early-stage
programs the company provides a variety of process development
activities, including upstream and downstream development and
optimization, analytical methods development, testing and
characterization. The scope of our services ranges from standalone
process development projects to full development and manufacturing
programs through commercialization. www.avidbio.com
This project has been funded in whole or in part
with Federal funds from the Department of Health and Human
Services; Office of the Assistant Secretary for Preparedness and
Response; Biomedical Advanced Research and Development Authority,
under Contract No. HHSO100201900018C.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024